ABSTRACT
We present a series of general and specific recommendations based on pathophysiologic considerations for managing the most common adverse effects of apremilast that lead to treatment discontinuation: diarrhea, nausea, and headache. The recommendations are based on a review of the literature and the experience of a multidisciplinary team of 14 experts including dermatologists, rheumatologists, neurologists, gastroenterologists, pharmacists, and nurses. We propose a series of simple algorithms that include clinical actions and suggestions for pharmacologic treatment. The adverse effects of apremilast can be managed from a multidisciplinary approach. The purpose of optimizing management is to bring clinical benefits to patients.
Subject(s)
Diarrhea/chemically induced , Headache/chemically induced , Nausea/chemically induced , Phosphodiesterase 4 Inhibitors/adverse effects , Thalidomide/analogs & derivatives , Combined Modality Therapy , Diarrhea/diet therapy , Diarrhea/drug therapy , Diarrhea/physiopathology , Disease Management , Headache/drug therapy , Headache/physiopathology , Headache/prevention & control , Humans , Nausea/diet therapy , Nausea/drug therapy , Nausea/physiopathology , Patient Care Team , Phosphodiesterase 4 Inhibitors/therapeutic use , Practice Guidelines as Topic , Psoriasis/drug therapy , Thalidomide/adverse effects , Thalidomide/therapeutic useABSTRACT
Breast cancer is the most commonly diagnosed cancer and is the leading cause of mortality due to all types of cancers among the female population worldwide. Results of clinical trials investigating the effect of ginger on chemotherapy-induced nausea and vomiting (CINV) in breast cancer patients are inconsistent. This study was aimed at obtaining a comprehensive overview of the current evidence regarding the effectiveness of ginger as an antiemetic modality for controlling CINV in breast cancer patients. All published randomized controlled trials in English were systematically searched on Google Scholar, PubMed, Scopus, and Cochrane search databases up to June 2018. The outcome variable of interest was severity and the frequency of nausea and vomiting in patients. A total of 50 studies were found through search databases. After excluding duplicates, the 42 remaining studies were screened, and finally, nine trials were included, which were published between 2012 and 2017. Two studies have examined the effect of ginger on the frequency of nausea, five studies on the frequency of vomiting, seven studies on the severity of nausea, and three studies on severity of vomiting. A study evaluated the effectiveness of ginger in improving dietary intake in CINV. Our investigation suggests that ginger may reduce nausea in the acute phase of chemotherapy in patients with breast cancer. The effect of ginger on nausea and vomiting in other conditions requires more high-quality clinical trials.
Subject(s)
Breast Neoplasms/complications , Nausea/diet therapy , Vomiting/diet therapy , Zingiber officinale/chemistry , Adult , Breast Neoplasms/drug therapy , Breast Neoplasms/pathology , Female , Humans , Middle Aged , Nausea/chemically induced , Randomized Controlled Trials as Topic , Vomiting/chemically inducedABSTRACT
Patients with breast cancer (PsBC) usually face with chemotherapy induced nausea and vomiting (CINV). The aim of this study was to assess the impact of nutritional counseling on CINV and quality of life (QoL) of PsBC. 150 PsBC were randomly assigned for receiving a personalized diet, which contained 1.2-1.5 g/kg of protein, 30% of energy from fat and 55-60% of energy from carbohydrate, a face to face nutrition education, and a pamphlet which contained beneficial nutrition information to reduce the severity of CINV before each chemotherapy session for three times (n = 75) or regular care (n = 75). CINV, QoL, and dietary intake were evaluated after each chemotherapy session. Nausea rating index, overall nausea index, and visual analog scale (P < 0.001) were dramatically lower in the intervention group. Global health status/QoL as well as physical functioning, role functioning, emotional functioning, and cognitive functioning (P < 0.001) were significantly better in the intervention group. Patients in the control group experienced more fatigue, nausea and vomiting, pain, dyspnea, loss of appetite, constipation, and diarrhea (P < 0.001). Nutrition counseling during adjuvant chemotherapy among PsBC reduced the occurrence of CINV and led to significant improvements in the QoL.
Subject(s)
Breast Neoplasms/drug therapy , Nausea/chemically induced , Nausea/diet therapy , Quality of Life , Vomiting/chemically induced , Adult , Chemotherapy, Adjuvant/adverse effects , Energy Intake , Female , Humans , Middle Aged , Patient Education as Topic , Precision Medicine , Vomiting/diet therapyABSTRACT
Opioids remain the standard of care for treating moderate to severe pain resulting from surgery or injury in cases of acute pain, and are recommended for patients who have not responded to nonopioid analgesics. Effective management of pain has an impact on clinical course and often depends on achieving an acceptable balance between opioid efficacy, safety, and tolerability. Common opioid-related adverse events such as nausea and vomiting are associated with an overall lower achievement of effective pain management and patient satisfaction. However, in practice, clinicians employ various strategies to maximize efficacy, minimize these adverse effects, and ensure the careful, judicious, and evidence-based use of opioids for patients who require them. Typical strategies for management and minimization of these types of adverse events include dose reduction, dose titration, opioid rotation, prescription for an antiemetic, and recommending the patient take opioids with food. Overall, the most straightforward approach that clinicians tend to employ that does not require additional visits or adjustment of prescriptions, is to recommend patients take opioids with food. However, given the current climate with opioids, it is critical and imperative that decisions for use of opioids be grounded in a solid and thorough evidence-base. In fact, several opioids are recommended to be taken explicitly with or without food because of interactions with abuse-deterrent technologies that can cause increased adverse events or inadequate analgesia. Therefore, we sought to review, synthesize, and summarize the literature for randomized, controlled trials and other studies to support the hypothesis that taking opioids with food reduces opioid-related events such as nausea and vomiting. Based on the current evidence we surveyed, the recommendation to take opioids with food does not appear to consistently and unequivocally reduce nausea and vomiting and, in many cases, increases the frequency of these adverse events in the studies we examined.
Subject(s)
Analgesics, Opioid/adverse effects , Analgesics, Opioid/therapeutic use , Eating , Nausea/chemically induced , Nausea/diet therapy , Pain/drug therapy , Vomiting/chemically induced , Vomiting/diet therapy , Adult , Aged , Aged, 80 and over , Female , Humans , Male , Middle AgedABSTRACT
Objective Conditioning regimens for hematopoietic stem cell transplantation (HSCT) are well known to cause severe gastrointestinal toxicities that often disturb the oral intake of the patients followed by poor nutrition and life-threatening infection. An oral elemental diet (ED) is an easily consumed and assimilated form of liquid nutrients mainly composed of amino acids. It alleviates the digestive loading from the intestine and is mainly used for enteral nutritional support in patients with Crohn's disease. We herein report, for the first time, the efficacy of ED for patients undergoing HSCT. Methods We evaluated the efficacy of ED in a prospective cohort study. The primary endpoint for this study was the hospitalization period. The secondary endpoint was the occurrence of oral mucositis, nausea, diarrhea and fever. Patients A total of 73 patients were consecutively enrolled between March 2011 and March 2013. Twenty-three patients underwent autologous HSCT and 50 patients underwent allogeneic HSCT. The first 21 patients did not receive ED (non-ED group; NEG) while in the successive 52 patients (ED group; EG), oral ED was started before conditioning and was continued until 28 days after transplantation. Results The patient characteristics were similar between the two groups. The mean duration of ED administration for EG was 28.7 days (range, 3-37 days), and the mean total-dose of ED administration was 1904 g (range, 240-2,960 g). The median hospitalization period was significantly shorter in EG compared to NEG, (34 days vs. 50 days; p=0.007). Grade 3-4 oral mucositis occurred less in EG than NEG (25% vs. 48%; p=0.06). Conclusion Oral ED may promote an early mucosal recovery and thereby shorten the duration of hospitalization.
Subject(s)
Enteral Nutrition/methods , Food, Formulated , Hematopoietic Stem Cell Transplantation , Nutritional Support/methods , Stomatitis/diet therapy , Stomatitis/prevention & control , Transplantation Conditioning/adverse effects , Adolescent , Adult , Aged , Diarrhea/diet therapy , Diarrhea/prevention & control , Female , Fever/diet therapy , Fever/prevention & control , Hospitalization , Humans , Male , Middle Aged , Mucous Membrane , Nausea/diet therapy , Nausea/prevention & control , Prospective Studies , Treatment OutcomeABSTRACT
Nausea and vomiting are among the most serious side effects of chemotherapy, in some cases leading to treatment interruption or chemotherapy dose reduction. Ginger has long been known as an antiemetic drug, used for conditions such as motion sickness, nausea-vomiting in pregnancy, and post-operation side effects. One hundred and fifty female patients with breast cancer entered this prospective study and were randomized to receive ginger (500 mg ginger powder, twice a day for 3 days) or placebo. One hundred and nineteen patients completed the study: 57 of them received ginger and 62 received ginger for the frst 3 chemotherapy cycles. Mean age in all patients was 48.6 (25-79) years. After 1st chemotherapy, mean nausea in the ginger and control arms were 1.36 (±1.31) and 1.46 (±1.28) with no statistically significant difference. After the 2nd chemotherapy session, nausea score was slightly more in the ginger group (1.36 versus 1.32). After 3rd chemotherapy, mean nausea severity in control group was less than ginger group [1.37 (±1.14), versus 1.42 (±1.30)]. Considering all patients, nausea was slightly more severe in ginger arm. In ginger arm mean nausea score was 1.42 (±0.96) and in control arm it was 1.40 (±0.92). Mean vomiting scores after chemotherapy in ginger arm were 0.719 (±1.03), 0.68 (±1.00) and 0.77 (±1.18). In control arm, mean vomiting was 0.983 (±1.23), 1.03 (±1.22) and 1.15 (±1.27). In all sessions, ginger decreased vomiting severity from 1.4 (±1.04) to 0.71 (±0.86). None of the differences were significant. In those patients who received the AC regimen, vomiting was less severe (0.64±0.87) compared to those who received placebo (1.13±1.12), which was statistically significant (p-value <0.05). Further and larger studies are needed to draw conclusions.
Subject(s)
Breast Neoplasms/drug therapy , Doxorubicin/adverse effects , Doxorubicin/therapeutic use , Nausea/diet therapy , Plant Extracts/therapeutic use , Vomiting/drug therapy , Zingiber officinale/chemistry , Adult , Aged , Antiemetics/therapeutic use , Antineoplastic Agents/adverse effects , Antineoplastic Agents/therapeutic use , Female , Humans , Middle Aged , Nausea/chemically induced , Prospective Studies , Vomiting/chemically inducedABSTRACT
Antineoplastic chemotherapy (CT) represents the systemic treatment of malignant tumors. It can be used alone or combined with surgery and / or radiotherapy. The cytotoxic agents used in chemotherapy work on both cancerous cells and noncancerous cells of the body, generally resulting in high toxicity. The biological aggressiveness of chemotherapy particularly affects rapidly replicating cells, such as those of the digestive tract, resulting in adverse effects that impair food intake, leading to compromised nutritional status and which may lead to cachexia. The main toxic effects of chemotherapy in the gastrointestinal tract include nausea, vomiting -these are the most frequent- constipation, diarrhea, xerostomia, mucositis, dysphagia and anorexia. Given the high frequency of such effects, nutritional intervention should be an integral part of cancer treatment, to maintain and/or improve the patient's nutritional status and reduce or minimize the side effects caused by treatment. Accordingly, the goal of this study is to review dietetic conduct in the process of caring for patients undergoing cancer chemotherapy.
Subject(s)
Antineoplastic Agents/adverse effects , Gastrointestinal Diseases/chemically induced , Gastrointestinal Diseases/diet therapy , Anorexia/chemically induced , Anorexia/diet therapy , Constipation/chemically induced , Constipation/diet therapy , Deglutition Disorders/chemically induced , Deglutition Disorders/diet therapy , Diarrhea/chemically induced , Diarrhea/diet therapy , Humans , Nausea/chemically induced , Nausea/diet therapy , Neoplasms/complications , Neoplasms/drug therapy , Nutritional Status , Stomatitis/chemically induced , Stomatitis/diet therapy , Vomiting/chemically induced , Vomiting/diet therapy , Xerostomia/chemically induced , Xerostomia/diet therapyABSTRACT
PURPOSE/OBJECTIVES: To determine the feasibility of administering a flavonoid-rich adjunctive treatment (Concord grape juice) for the management of chemotherapy-induced nausea and vomiting (CINV); to evaluate the usefulness of existing measures for assessing CINV frequency and severity, quality of life, control over life events, and psychological state; to identify any actual or potential adverse events associated with frequent grape juice intake; and to provide preliminary data concerning the effect of Concord grape juice on CINV, quality of life, perceived control over life events, and psychological state. DESIGN: Double-blind, randomized clinical trial. SETTING: A cancer center in an academic health science center in the northeastern United States. SAMPLE: 77 adult patients with cancer receiving moderately or highly emetogenic chemotherapy agents. METHODS: Participants drank 4 oz. of grape juice or placebo prior to meals for one week following each of four chemotherapy treatment cycles. They recorded frequency, duration, and distress of nausea, vomiting, and retching daily, beginning the evening of chemotherapy administration and continuing for seven days. Data were analyzed with generalized estimating equations methodology to model differences between groups over time. MAIN RESEARCH VARIABLES: Nausea and vomiting frequency, duration, and distress; quality of life; control over decision making; and psychological state. FINDINGS: Nausea and vomiting frequency, duration, and distress were lower for experimental group members, although a high attrition rate (50%) resulted in insufficient power to detect statistically significant differences over time. Greater levels of anxiety, depression, and hostility at baseline were related to nausea and vomiting, quality of life, and perceived control over decision making. CONCLUSIONS: The effect of grape juice flavonoids on CINV should be investigated further with a larger sample to determine whether preliminary findings are supported. Alterations to the study protocol will be necessary to decrease attrition. IMPLICATIONS FOR NURSING: Flavonoid-rich fruits and vegetables may provide additional protection against CINV. If the compounds work, they would offer a low-cost, readily available adjunctive treatment for the management of CINV.
Subject(s)
Antineoplastic Agents/adverse effects , Beverages , Nausea/diet therapy , Neoplasms/drug therapy , Vitis , Vomiting/diet therapy , Adult , Aged , Eating , Female , Flavonoids/administration & dosage , Humans , Male , Middle Aged , Nausea/chemically induced , Neoplasms/nursing , Neoplasms/psychology , Oncology Nursing/methods , Pilot Projects , Psychometrics , Quality of Life , Treatment Outcome , Vomiting/chemically inducedABSTRACT
Emil is a nutrient adjuvant which provide relief of nausea and vomiting symptoms of pregnancy. It contains Vitamin B, Potassium citrate and Sodium citrate and is suitable for children, adults, hospital patients and disabled persons.
Subject(s)
Dietary Supplements , Nausea/diet therapy , Vomiting/diet therapy , Adult , Aged , Aged, 80 and over , Child , Citrates/therapeutic use , Disabled Persons , Female , Humans , Potassium Citrate/therapeutic use , Pregnancy , Sodium Citrate , Thiamine/therapeutic use , Young AdultABSTRACT
No disponible
Subject(s)
Humans , Neoplasms/complications , Nutrition Disorders/epidemiology , Malnutrition/diet therapy , Nutrition Therapy/methods , Evaluation of Results of Therapeutic Interventions , Nutritional Support/methods , Risk Factors , Anorexia/diet therapy , Nausea/diet therapy , Constipation/diet therapy , Deglutition Disorders/diet therapyABSTRACT
Nausea and vomiting are symptoms associated with a wide variety of diseases and particular life conditions, such as pregnancy. The symptoms may occur in acute form or chronically depending on the underlying pathogenesis. In some cases, nausea and vomiting are directly triggered by food, e.g. in patients suffering from food allergy or food intolerances. In other cases, food is not the primary cause but dietetic manipulations may still contribute to the management of the nausea and vomiting. Therefore, food plays an important pathophysiological and therapeutic role in nausea and vomiting. In the present article, we describe the most relevant nutrient triggers for nausea and vomiting, discuss food allergy and intolerance as cause of nausea and vomiting, propose a clinical classification of nausea and vomiting, and present in detail dietetic and other therapeutic strategies of relevance for the management of nausea and vomiting.
Subject(s)
Food/adverse effects , Nausea/etiology , Nutritional Physiological Phenomena , Vomiting/etiology , Female , Food Hypersensitivity/complications , Humans , Nausea/diet therapy , Nausea/physiopathology , Pregnancy , Vomiting/diet therapy , Vomiting/physiopathologySubject(s)
Dietary Carbohydrates/therapeutic use , Diarrhea/diet therapy , Diarrhea/physiopathology , Stomatitis/diet therapy , AIDS-Related Opportunistic Infections , Energy Requirement/physiology , Nutritional Requirements , Enteral Nutrition/methods , Parenteral Nutrition/methods , Nutritional Sciences/physiology , Nausea/diet therapy , Nausea/physiopathology , Acquired Immunodeficiency Syndrome/physiopathology , Vomiting/diet therapy , AnorexiaSubject(s)
Hyperemesis Gravidarum , Nausea , Pregnancy Complications , Female , Humans , Hyperemesis Gravidarum/diet therapy , Hyperemesis Gravidarum/etiology , Hyperemesis Gravidarum/therapy , Nausea/diet therapy , Nausea/etiology , Nausea/therapy , Pregnancy , Pregnancy Complications/diet therapy , Pregnancy Complications/etiology , Pregnancy Complications/therapyABSTRACT
No disponible
Subject(s)
Antineoplastic Agents/adverse effects , Antineoplastic Agents/radiation effects , Nutritional Status , Nutritional Status/radiation effects , Radiotherapy/adverse effects , Radiotherapy/methods , Radiotherapy , Eating/physiology , Eating/radiation effects , Eating , Gastrointestinal Neoplasms/complications , Gastrointestinal Neoplasms/diagnosis , Gastrointestinal Neoplasms/diet therapy , Anorexia/diet therapy , Anorexia/diagnosis , Social Support , Psychosocial Deprivation , Nausea/diagnosis , Nausea/diet therapySubject(s)
Antineoplastic Agents/adverse effects , Nausea/diet therapy , Nutritional Physiological Phenomena , Vomiting/diet therapy , Anorexia/chemically induced , Anorexia/diet therapy , Anorexia/prevention & control , Diarrhea/chemically induced , Diarrhea/diet therapy , Diarrhea/prevention & control , Food Services , Humans , Nausea/chemically induced , Nausea/prevention & control , Selective Serotonin Reuptake Inhibitors/therapeutic use , Stomatitis/chemically induced , Stomatitis/diet therapy , Stomatitis/prevention & control , United States , Vomiting/chemically induced , Vomiting/prevention & controlABSTRACT
Continuous quality improvement presents many avenues for change. We decided to evaluate the number of complaints of nausea and vomiting from patients receiving preservative-free (PF) epidural morphine reinjections. A systematic study of this problem involved a survey of all patients receiving epidural pain management. Staff from the Department of Anesthesia and pain management nurses monitored the results, and after 2 months recommendations were made to change the diet of these patients for the first 24-hour postoperative period. Only those patients who received PF epidural morphine reinjections had problems with nausea and vomiting. Therefore, only these patients were started on the epidural diet regimen. After several modifications of the diet, we found that there were 80% less complaints of nausea and vomiting in patients adhering to this diet plan while receiving PF epidural morphine.